Please assess the completion status of the following clinical trial:

Trial Title: Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able and willing to sign the Informed Consent Form.~* Subject undergoes a transrectal prostate biopsy as part of the standard care in the Radboudumc (Nijmegen), Canisius Wilhelmina hospital (Nijmegen) or Catharina hospital (Nijmegen) (because of suspicion of prostate cancer).~Exclusion Criteria:~* Inability to receive ciprofloxacin (e.g. documented history of sensitivity to medicinal products or excipients similar to those found in the antibiotic prophylaxis, relevant history or presence of cardiovascular disorders)~* Inability to receive either co-trimoxazole, fosfomycin and pivmecillinam/augmentin prophylaxis for any reason (e.g. documented history of sensitivity to medicinal products or excipients similar to those found in the antibiotic prophylaxis)~* Inability to understand the nature of the trial and the procedures required.~* Individuals with an urinary tract infection or acute prostatitis within 14 days prior to intervention.~* Individuals who receive antibiotics within 14 days before prostate biopsy.~* Individuals who fail to send a rectum swab to the microbiology laboratory.~* Individuals whose rectal swab shows no growth on a (growth) control MacConkey agar without antibiotics.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Targeted antimicrobial prophylaxis (Type: EXPERIMENTAL): Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~* trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~* fosfomycin 3 g orally 2 hours before prostate biopsy, or~* pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy.
- Routine empirical prophylaxis (Type: ACTIVE_COMPARATOR): Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).